SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is experiencing heightened volatility as investors weigh sharp declines in major technology stocks against shifting geopolitical developments and uncertainty regarding Federal Reserve interest rate policy. Community sentiment is deeply polarized, with active debates centered on whether this market environment represents a healthy rotation into value sectors or the beginning of a broader correction driven by unsustainable valuation levels.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing a parabolic rally driven by an AI-induced memory supercycle and persistent NAND supply shortages that investors believe will last for years. While the stock has reached extreme valuations, the community remains sharply divided between bulls chasing the intense momentum and bears anticipating a massive rug pull due to the lack of significant pullbacks.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense investor focus as it nears earnings, driven by a surge in demand for AI-critical memory and a strategic infrastructure agreement with Anthropic. The community is actively debating whether the stock's massive rally is a sustainable re-rating based on structural AI demand or an overextended bubble primed for a post-earnings pullback.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as traders closely watch a divergence between semiconductor strength and significant volatility in other major tech names, alongside concerns regarding liquidity and geopolitical risks. The community is actively debating whether current price action signals a healthy rotation or a deeper structural correction as market participants navigate overnight volatility and uncertain macroeconomic signals.

Roundhill ETF Trust - Roundhill Memory ETF

Roundhill Memory ETF ($DRAM) is trending as investors aggressively position into memory and storage infrastructure, viewing it as a critical bottleneck for AI scaling rather than a typical cyclical semiconductor play. The community is focused on the sector's long-term supply constraints and pricing power, with many traders actively accumulating positions in anticipation of upcoming major earnings reports and potential structural re-ratings within the broader AI supply chain.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense downward pressure following its recent IPO as investors grapple with high valuations, aggressive cash-burning AI initiatives, and fears of significant share dilution upon the expiration of lockup periods. The community remains deeply divided, with vocal bears labeling the stock an overhyped retail trap, while long-term bulls defend the company's visionary growth potential and institutional backing.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors react to two White House executive orders designed to accelerate national quantum computing and sensing capabilities, a move the community views as a major validation of the company's strategic alignment with U.S. defense interests. While many participants are actively discussing the potential for a long-term rally and upcoming corporate milestones, some traders remain cautious, highlighting the high volatility and current market pressure impacting the share price.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is experiencing intense community focus as traders debate the sustainability of its recent rally, fueled by anticipation of upcoming Russell index inclusion and potential data center lease announcements. While bulls highlight the stock's pivot to high-demand AI infrastructure and institutional accumulation patterns, bears remain cautious about the lack of concrete contracts and the stock's high volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as investors closely watch the upcoming maintenance trial results for its weight-loss candidate, VK2735, which remains a key catalyst for potential acquisition or partnership. The community is actively debating the company's prospects for independent commercialization versus a buyout, while keeping a close eye on the competitive landscape within the obesity drug sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following the failure of its Phase 3 SigVig-002 trial for sigvotatug vedotin, a significant setback for the company's oncology pipeline that has investors questioning its growth strategy and leadership. The community is actively debating the future of Pfizer's oncology investments, the impact of recent leadership transitions, and whether the stock's dividend yield justifies holding through the ongoing clinical and structural uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nasdaq, S&P 500, Dow Futures Mixed As Hormuz Tensions Ease, China Tightens Export Curbs: Why SPCX, MU, INTC, SLS, MLTX, GETY Are In Focus

Equity

Stocktwits data showed retail sentiment has remained ‘bullish’ on SPY and QQQ. 

SLS Stock Slips Overnight: Shareholders Approve 20M New Shares, CEO Awarded 1M RSUs

CEO Angelos Stergiou's equity award will vest over four years, increasing his ownership stake to 1.76 million shares.

All Eyes On SLS Stock Ahead Of Annual Shareholder Meet – What’s On The Agenda?

Shareholders are set to vote on five proposals, including one to increase the number of shares available under the 2023 Equity Incentive Plan.

SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute

Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.

SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers

Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.

SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout 

CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."

SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS

Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.

SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms

Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ahead of the Regal data release.

SLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial Readout 

The company plans to move quickly toward a pre-BLA meeting with the FDA and a potential filing if the REGAL trial reports positive results.

SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst

Retail speculation intensified as short interest in SLS climbed to a record high of 30.7% ahead of the final Regal catalyst.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Retail investors are piling into the stock as the Cost-to-Borrow fee skyrockets above 90% and share inventory vanishes.

Investors are closely watching for the imminent 80th trial event announcement, which is expected to trigger significant market volatility.

Speculation intensifies over a multi-billion dollar acquisition by major pharmaceutical players as patents continue to expire.

The debate continues among traders regarding the ongoing Phase 3 study results and whether the clinical data will achieve statistical significance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '27	--	-$0.13	--	N/A
Q1 '27	--	-$0.05	--	N/A
Q2 '26	-$0.05	--	--	N/A
Q1 '26	-$0.06	-$0.05	16.67%	BEAT
Q4 '25	-$0.06	-$0.05	21.05%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLSSELLAS Life Sciences Group Inc

Upcoming Earnings: Q2 '27

Historical Earnings

Latest SLS News